NCT06351904View on ClinicalTrials.gov

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 3, 2024

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Interventions
DRUG

RAG-01

RAG-01 is a therapeutic small activating RNA (saRNA) duplex molecule comprised of two partially chemically modified complementary oligonucleotide strands.

Trial Locations (3)

2065

RECRUITING

GenesisCare North Shore, St Leonards

3050

RECRUITING

The Royal Melbourne Hospital, Melbourne

3199

RECRUITING

Peninsula & South Eastern Haematology and Oncology Group, Melbourne

All Listed Sponsors
lead

Ractigen Therapeutics.

OTHER